Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Stem Cells & Perinatal Therapies

Cell and perinatal products: promise, evidence, quality and clinical limitations.

RheumaView · Cellular therapy

CAR-T in rheumatology

A new ambition for autoimmune disease: lasting control after a finite treatment course.

By Olga Goodman, MD
Evidence reviewed · 25 September 2026

Engineered recognitionA conceptual CD19-directed CAR on a T cell recognizes a B-cell target. This is an illustration, not a quantitative or product-specific model.Engineered T cellB-cell targetRECOGNITIONChimeric antigen receptorCD19 example
Conceptual illustration · targets and platforms differ.
Explore the mechanism →
Professionals · English

Disease-specific evidence, safety and referral decisions.

Open the professional reading room →

Watch. Explore. Decide.

CASCADE brings the cellular story and clinical reasoning into an interactive learning space.

Video · 1:55 · English audio

CAR-T, seen in motion

From T-cell collection to receptor design and recognition of a CD19-positive B cell.

Watch the film →

Professionals · English · Guided learning

AnnaMaria · Explore CD19

Follow the animated mechanism, a fictional lupus-nephritis case and a simulated-data exercise.

Start the activity →

Professionals · English · Case challenge

Carmen · Weigh the choices

Choose patient priorities, evaluate the medical facts and compare your reasoning with the scenario.

Start the activity →

The professional activities use fictional cases. Simulated results and scenario answer keys are clearly distinguished from clinical evidence.

The collection, at a glance.

Choose a chapter or search the complete text.

01

The idea & the biology

Mechanism, targets and cell platforms.

More in this section · 1
02

Evidence by disease

Read the diagnosis, design and denominator.

More in this section · 5
03

Clinical decisions

From referral to treatment and comparison.

More in this section · 1
04

Safety & follow-up

Acute toxicity, recovery and durability.

05

The next generation

Donor cells, RNA and in vivo approaches.

06

Research & practical resources

Trials, consultation tools and original sources.

More in this section · 4

Find the disease.

Direct routes into the evidence.

Remission is a result. Cure is a larger claim.

Keep disease control, medication withdrawal, immune recovery and reversal of damage separate. How to read the outcomes →

Safety is part of the evidence.

The September 2026 rap-cel and zola-cel disclosures concern distinct programs. Read the safety context →

Connect the therapy with the disease.

Personal educational publication; not a clinic portal or an offer to administer CAR-T. Any private expert opinion is separate from clinic care and accounts, paid directly and not billed to insurance.

Original educational content by Dr. Olga Goodman / Olga Goodman, MD. Copying without attribution prohibited.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: CAR-T